LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...

The Spectra Optia Apheresis System (Terumo BCT) is an apheresis and cell collection platform which can be used in the treatment of sickle cell disease. The purpose of this evaluation is to assess the ...

Recent peer-reviewed study supports what patients shared with their own voices: Automated red blood cell exchange improves the lives of people struggling with sickle cell disease LAKEWOOD, Colo., Nov.

LONDON, Feb. 14, 2024 /PRNewswire/ -- Children, young people, and adults across England suffering from sickle cell disease will soon benefit from better care closer to where they live, following the ...

The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity. The Food and Drug Administration (FDA) has issued an Emergency Use ...

Sepsis is one of the most frequent causes of death worldwide, claiming nearly 11 million lives, accounting for 20% of all global deaths [1, 2] and taking more lives than cancer [3]. This is more than ...

In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo BCT), announced that its Spectra ...

The Agency believes that the ability to manage the cytokine storm associated with COVID-19 may decrease patient morbidity. The Food and Drug Administration (FDA) has issued an Emergency Use ...